

**Frequently Asked Questions (FAQs) for (Reissue RFA-NR-22-001) RFA-NR-23-003
Evaluating the Impact of Pandemic Era related Food and Housing
Policies and Programs on Health Outcomes in Health Disparity Populations (R01 Clinical Trial Optional)**

APPLICATION SUBMISSION

Q1. When are applications due?

A1. Earliest submission date is April 01, 2023. All applications are due by May 01, 2023 by 5:00 PM local time of applicant organization. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Q2. Am I required to submit a letter of intent?

A2. A letter of intent is not required, is not binding, and does not enter into the review of a subsequent application. The information that it contains allows IC staff to estimate the potential review workload and plan review. Letter of intent due April 01, 2023 and should be sent to:

FOAReviewContact@csr.nih.gov

Q3. Does the application have a page limit?

A3. All page limitations described in the SF424 Application Guide and the [Table of Page Limits](#) must be followed.

Q4. How should I submit my application?

A4. All applications must be submitted electronically. Applicants should follow instructions in the SF424 (R&R) Application Guide, except where instructed to do otherwise in the [Funding Opportunity Announcement](#) or in a Notice from the [NIH Guide for Grants and Contracts](#)

Q5. Are foreign institutions eligible to apply?

A5. Non-domestic (non-U.S.) entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the [NIH Grants Policy Statement](#) are allowed.

Q6. Are applications with multiple Principal Investigators (PIs) permitted?

A6. Yes. For institutions/organizations proposing multiple PDs/PIs, visit the Multiple Program Director/Principal Investigator Policy and submission details in the Senior/Key Person Profile (Expanded) Component of the SF424 (R&R) Application Guide.

Q7. Can an organization submit more than one application?

A7. Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The NIH will not accept duplicate or highly overlapping applications under review at the same time, per [2.3.7.4 Submission of Resubmission Application](#). This means that the NIH will not accept:

- A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
- A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.

- An application that has substantial overlap with another application pending appeal of initial peer review (see [2.3.9.4 Similar, Essentially Identical, or Identical Applications](#)).

RESEARCH OBJECTIVES AND SCOPE

Q8. How is this reissued RFA different from the original version published in 2022?

A8. Rather than focusing specifically on COVID-19, this RFA focuses on broader pandemic era food and housing related policies. For the purposes of this RFA, pandemic era is defined as the period from 2020 to present which includes ongoing widespread adverse social, behavioral, and economic disruptions. Additionally, RFA-NR-22-001 was focused on the COVID-19 pandemic. RFA-NR-23-003 focuses more broadly on the widespread adverse social, behavioral, and economic disruptions during the period 2020 to present, caused by COVID-19 but also other concomitant viral threats. RFA-NR-23-003 also encourages studies that examine how discontinuation of food/nutrition and/or housing security programs influence health outcomes and health equity. Applicants should also pay close attention to the list of ICOs that are participating on RFA-NR-23-003, as it differs from RFA-NR-22-001. In addition, a Plan for Enhancing Diverse Perspectives (PEDP) was encouraged in RFA-NR-22-001; however, a PEDP is now required.

Q9. How can I determine whether my research topic is a good fit for RFA-NR-23-003?

A9. Applicants are encouraged to contact the Scientific/Research contact at the intended IC listed in this [funding opportunity](#) announcement to ensure that proposed aims of the project are consistent with IC mission and priorities.

Q10. If my research project is relevant to more than one NIH Institute (IC), what information should I use to determine which IC is the best to receive my application?

A10. Applicants whose research may be relevant to more than one NIH IC are highly encouraged to discuss potential research aims with the Scientific/Research Contacts at participating ICs well in advance of the application deadline to ensure overall fit of the proposed research with programmatic priorities, as stated in the funding opportunity announcement. The Contacts are the most appropriate individuals to help applicants identify alternative funding opportunity announcements (FOAs) if it is determined that the applicant's research goals are not well-aligned with any of the participating IC's research priorities.

Q11. This RFA states that clinical trials are optional. How are clinical trials determined?

A11. Applications that propose a clinical trial and applications that do not propose a clinical trial will be accepted for this funding opportunity. Investigators who propose to conduct a clinical trial should review the NIH Definition of a Clinical [Trial](#). A research study in which one or more human subjects are [prospectively assigned](#) to one or more [interventions](#) (which may include placebo or other control) to evaluate the effects of those interventions on [health-related biomedical or behavioral outcomes](#) meets the NIH definition of a clinical trial intervention. A decision tool is also available to assist in making the determination about whether or not the study is a clinical trial.

Q 12. If I plan to use existing data and/or data linkages in my study, do I need to already have access to the existing data when I apply, or can I wait until I get the grant so I can use some of the R01 funding to pay for gaining access and/or linking datasets?

A12. Ideally, applicants should demonstrate current access to data. Applicants may include a plan for obtaining access to data and requesting funding to pay for access. This might be deemed acceptable. Applicants are encouraged to reach out to one or more of the [Scientific/Research Contacts from the participating Institutes](#) to consult about this issue. Additionally, instructions for budgets can be found in the SF424 (R&R) Application Guide and must be followed.

APPLICATION REVIEW

Q 13. Where will my application be reviewed?

A13. Applications will be evaluated for scientific and technical merit by (an) appropriate Scientific Review Group(s) convened by the Center for Scientific Review (CSR), in accordance with [NIH peer review policy and procedures](#), using the stated review criteria. Assignment to a Scientific Review Group will be shown in the eRA Commons.

Q 14. What factors determine what study panel will review my application?

A14. All grant applications submitted to the NIH go to the Division of Receipt and Referral (DRR) within the CSR. For more information on the Receipt and Referral process, see [CSR: Submission and Assignment Process](#). Prior to submitting your application, questions regarding the scientific review process can be discussed with the Scientific/Research Contact(s) from the participating IC(s) or with a Scientific Review Officer from CSR.

AWARD SELECTION

Q 15. On what basis are applications selected for funding?

A15. Applications will compete for available funds with all other recommended applications submitted in response to this FOA. Following initial peer review, recommended applications will receive a second level of review by the National Advisory Council for Nursing Research. The following will be considered in making funding decisions: (1) Scientific and technical merit of the proposed project as determined by scientific peer review; (2) Availability of funds; and (3) Relevance of the proposed project to program priorities. Applicants are highly encouraged to discuss potential research aims with the Scientific/Research Contacts from the participating ICs to determine fit with programmatic research priorities

Q 16. What is the anticipated number of awards funded under RFA-NR-23-003?

A16. Issuing IC and partner components intend to commit an estimated total of \$4,000,000 to fund 4-6 awards.

RESEARCH/IC-SPECIFIC QUESTIONS

For questions that are specific in nature, potential applicants are encouraged to reach out and consult with the Scientific/Research Contacts that are named in the RFA and Notices prior to submitting an

application. Discussions with the contacts from each relevant IC about potential research aims can be very helpful in determining project fit and alignment with the IC's programmatic research priorities.

KEY OF ABBREVIATED TERMS

AIDS – Acquired Immunodeficiency Syndrome

ART – Assisted Referral Tool

COVID-19 – Coronavirus Disease 2019

CSR – Center for Scientific Review

DRR – CSR Division of Receipt and Referral

ESIs – Early-Stage Investigators

FOA – Funding Opportunity Announcement

HIV – Human Immunodeficiency Virus

ICs – NIH Institutes, Centers, and Offices

NIMH – National Institute of Mental Health

NIMHD – National Institute of Minority Health and Health Disparities

NINR – National Institute of Nursing Research

ODP – Office of Disease Prevention

PDs/PIs – Program Directors/Principal Investigators

RFA – Request for Applications